Feb 4 2010
EUCODIS Bioscience, a company
providing customized enzymes to the pharmaceutical, chemical, and other
industries, announced today that it has received a cash injection of EUR 2
million from existing shareholders.
The Company will use these funds to swiftly add new enzyme families to
its product portfolio and to accelerate the development of international
markets. At the same time, EUCODIS Bioscience is expanding its manufacturing
capacity in pace with growing customer demand for its novel enzymes.
Commenting on the capital injection Thomas Fischer, CEO of EUCODIS
Bioscience, said: "Following several product launches in 2009 and the recent
expansion of our lipases family to 20 enzymes we continue to build our order
book. Accordingly, our revenues will finance a good part of our expenses and
investments this year."
Fischer continued: "Given the wealth of business opportunities in front
of us, we are extremely pleased that the cash injection will help us to
broaden our product range and to ramp up our sales and marketing efforts."
EUCODIS Bioscience' shareholders Pontis Capital, Wiener Wachstumsfonds,
IBG, and ARAX participated in the cash injection.
Harald Schuerz, Managing Director of Wiener Wachstumsfonds, commented:
"We are delighted that the market clearly confirms the business model of
EUCODIS Bioscience. The commercial focus and the industrial mindset of their
team are impressive. In light of their track record and the market potential,
this company will soon be an Austrian IPO candidate."
Thomas Moser, Managing Partner at Pontis Capital, commented: "We have
been impressed with the progress EUCODIS Bioscience has made in
commercializing their experience in enzyme development. In addition, they
have established a proven technology for the directed evolution of enzymes
and have developed a unique expertise in manufacturing specialty enzymes.
This provides the right ingredients to make EUCODIS Bioscience a preeminent
supplier to the white biotechnology industry."
SOURCE EUCODIS Bioscience